 Angiotensin II Type 1 Receptor Blockers
"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
| Descriptor ID |
D047228
|
| MeSH Number(s) |
D27.505.519.162.500
|
| Concept/Terms |
Angiotensin II Type 1 Receptor Blockers- Angiotensin II Type 1 Receptor Blockers
- Type 1 Angiotensin Receptor Antagonists
- Type 1 Angiotensin Receptor Blockers
- Angiotensin II Type 1 Receptor Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".
This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in UAMS Profiles by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 | | 2019 | 0 | 2 | 2 | | 2018 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2012 | 1 | 2 | 3 | | 2011 | 2 | 2 | 4 | | 2010 | 2 | 2 | 4 | | 2009 | 1 | 2 | 3 | | 2008 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2005 | 0 | 2 | 2 | | 2004 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles over the past ten years.
-
Salah HM, Calcaterra G, Mehta JL. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):503-507.
-
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, S?nchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019 08 02; 20(1):292.
-
Fouda AY, Fagan SC, Ergul A. Brain Vasculature and Cognition. Arterioscler Thromb Vasc Biol. 2019 04; 39(4):593-602.
-
Sedl?kov? L, Kikerlov? S, Huskov? Z, Cervenkov? L, Ch?bov? VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kr?tk? V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5).
-
Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis. 2018 Aug; 12(8):217-231.
-
Fouda AY, Artham S, El-Remessy AB, Fagan SC. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence. Clin Sci (Lond). 2016 Feb; 130(4):221-38.
-
Fouda AY, Alhusban A, Ishrat T, Pillai B, Eldahshan W, Waller JL, Ergul A, Fagan SC. Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke. Mol Neurobiol. 2017 01; 54(1):661-670.
-
Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron. 2015; 130(3):159-68.
-
Soliman S, Ishrat T, Fouda AY, Patel A, Pillai B, Fagan SC. Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke. Transl Stroke Res. 2015 Aug; 6(4):309-22.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|